All sponsors

Genrix (Shanghai) Biopharmaceutical Co., Ltd.

Clinical trial pipeline · active industry-sponsored Phase 1/2 to Phase 3 trials · updated 2026-11-18
ACTIVE TRIALS11
PHASE 3 / 2-33
RECRUITING4
READOUTS ≤12 MONTHS4
READOUT SLIPPED >6 MO20%

Delay Index: of 5 active trials registered more than a year ago, 1 have moved their primary completion (readout) date by more than 6 months since first registration (median +0.0 months). See all sponsors →

Open Genrix (Shanghai) Biopharmaceutical Co., Ltd. on the live radar map →
TRIALPHASESTATUSCONDITIONNPRIMARY COMPLETION
GR1802 injection
NCT06315426
P2Active, not recruitingAllergic Rhinitis2402025-05
GR1802 injection
NCT07154342
P3RecruitingAllergic Rhinitis, Seasonal1502026-04-30
GR1803 injection
NCT07090954
P1/2Not yet recruitingMultiple Myeloma322026-07-31
GR1803 injection
NCT06566547
P2Active, not recruitingMultiple Myeloma1162027-05-12 (+9 mo)
GR1802 injection
NCT07199257
P3Not yet recruitingAllergic Rhinitis, Seasonal1442027-05-15
GR1803 injection
NCT07348055
P1/2RecruitingSystemic Lupus Erthematosus; Auto Immune Disease442027-06-01
GR1803
NCT06952075
P2RecruitingMultiple Myleoma302027-07-01
GREVIT-II
NCT07930039
P2Not yet recruitingVitiligo1202028-05
GREVIT
NCT07647237
P1/2Not yet recruitingVitiligo1162028-06
low dose GR1603 in phase Ⅰb
NCT06015230
P1/2Active, not recruitingLupus Erythematosus, Systemic1362028-06-10
GR1803 injection
NCT07452198
P3RecruitingMultiple Myeloma3582029-03